{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:04:21Z","timestamp":1790741061505,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004033","name":"Johannes Gutenberg-Universit\u00e4t Mainz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008963","name":"Spanish Society of Medical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008963","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.tranon.2026.103003","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:45:28Z","timestamp":1788223528000},"page":"103003","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["EORTC-1607-GITCG\/ABC-09: Open-label first-line, single-arm phase II study of CisGem combined with pembrolizumab in patients with advanced or metastatic biliary tract cancer"],"prefix":"10.1016","volume":"72","author":[{"given":"Angela","family":"Lamarca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9891-5046","authenticated-orcid":false,"given":"Annett","family":"Maderer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2272-3678","authenticated-orcid":false,"given":"Mair\u00e9ad G.","family":"McNamara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9186-1604","authenticated-orcid":false,"given":"John A.","family":"Bridgewater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Macarulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3959-4120","authenticated-orcid":false,"given":"Jorge","family":"Adeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Hubner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Lordick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3234-8891","authenticated-orcid":false,"given":"Friedrich","family":"Foerster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Weinmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter R.","family":"Galle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Leurquin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine I.","family":"Marreaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murielle E.","family":"Mauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1999-0863","authenticated-orcid":false,"given":"Juan W.","family":"Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Moehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.tranon.2026.103003_bib0001","doi-asserted-by":"crossref","first-page":"104003","DOI":"10.1016\/j.esmoop.2024.104003","article-title":"ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. ESMO Clinical Practice Guideline interim update on the management of biliary tract cancer","volume":"10","author":"Vogel","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.tranon.2026.103003_bib0002","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2026.103003_bib0003","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus Gemcitabine and Cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid."},{"key":"10.1016\/j.tranon.2026.103003_bib0004","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.tranon.2026.103003_bib0005","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tranon.2026.103003_bib0006","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S2468-1253(24)00119-5","volume":"9","author":"Vogel","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.tranon.2026.103003_bib0007","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tranon.2026.103003_bib0008","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tranon.2026.103003_bib0009","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N. Engl J. Med."},{"key":"10.1016\/j.tranon.2026.103003_bib0010","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","article-title":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","volume":"24","author":"Harding","year":"2023","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.tranon.2026.103003_bib0011","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.gastha.2023.01.009","article-title":"Treatment patterns and survival in locally advanced or metastatic biliary tract cancer using SEER medicare data","volume":"2","author":"Danese","year":"2023","journal-title":"Gastro Hep Adv."},{"key":"10.1016\/j.tranon.2026.103003_bib0012","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","article-title":"Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study","volume":"9","author":"Oh","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.tranon.2026.103003_bib0013","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.3390\/cells12162098","article-title":"Lacking immunotherapy biomarkers for biliary tract cancer: a comprehensive systematic literature review and meta-analysis","volume":"12","author":"Frega","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.tranon.2026.103003_bib0014","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/149185","article-title":"Chronic inflammation and cytokines in the tumor microenvironment","volume":"2014","author":"Landskron","year":"2014","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.tranon.2026.103003_bib0015","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s00292-021-00948-3","article-title":"MSI testing: what's new? What should be considered?","volume":"42","author":"Ruschoff","year":"2021","journal-title":"Pathologe"},{"key":"10.1016\/j.tranon.2026.103003_bib0016","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.canlet.2019.05.003","article-title":"Treg-mediated acquired resistance to immune checkpoint inhibitors","volume":"457","author":"Saleh","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.tranon.2026.103003_bib0017","doi-asserted-by":"crossref","first-page":"20699","DOI":"10.1002\/cam4.6628","article-title":"Survival benefit and biomarker of PD-1 inhibitor combination therapy in first-line of advanced biliary tract cancer: a retrospective study","volume":"12","author":"Guo","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.tranon.2026.103003_bib0018","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.tranon.2026.103003_bib0019","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/s41416-020-1018-0","article-title":"Suppressive myeloid cells are expanded by biliary tract cancer-derived cytokines in vitro and associate with aggressive disease","volume":"123","author":"Ware","year":"2020","journal-title":"Br J. Cancer"},{"key":"10.1016\/j.tranon.2026.103003_bib0020","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-023-00846-y","article-title":"Myeloid-derived suppressor cells in cancer and cancer therapy","volume":"21","author":"Lasser","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.103003_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111384","article-title":"Circulating monocytes associated with anti-PD-1 resistance in human biliary cancer induce T cell paralysis","volume":"40","author":"Keenan","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.tranon.2026.103003_bib0022","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3892\/ol.2023.13967","article-title":"Monocyte subsets associated with the efficacy of anti\u2011PD\u20111 antibody monotherapy","volume":"26","author":"Ohkuma","year":"2023","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.tranon.2026.103003_bib0023","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nm.4466","article-title":"High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy","volume":"24","author":"Krieg","year":"2018","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.tranon.2026.103003_bib0024","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.3390\/ijms23073636","article-title":"Neutrophil to lymphocyte ratio: an emerging marker of the relationships between the immune system and diseases","volume":"23","author":"Buonacera","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tranon.2026.103003_bib0025","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.3390\/biom13121803","article-title":"Neutrophil-to-lymphocyte ratio (NLR) in NSCLC, gastrointestinal, and other solid tumors: immunotherapy and beyond","volume":"13","author":"Mosca","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.tranon.2026.103003_bib0026","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41467-021-20935-9","article-title":"Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors","volume":"12","author":"Valero","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tranon.2026.103003_bib0027","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.21873\/anticanres.15781","article-title":"Neutrophil-to-lymphocyte ratio to predict the efficacy of immune checkpoint inhibitor in upper gastrointestinal cancer","volume":"42","author":"Booka","year":"2022","journal-title":"Anticancer Res."},{"key":"10.1016\/j.tranon.2026.103003_bib0028","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1186\/s12885-025-13811-y","article-title":"Neutrophil-to-lymphocyte ratio-based prognostic score can predict outcomes in patients with advanced non-small cell lung cancer treated with immunotherapy plus chemotherapy","volume":"25","author":"Liao","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.tranon.2026.103003_bib0029","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s12094-020-02509-1","article-title":"Prognostic value of neutrophil-to-lymphocyte ratio in advanced cancer patients receiving immunotherapy","volume":"23","author":"Vinal","year":"2021","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.tranon.2026.103003_bib0030","doi-asserted-by":"crossref","first-page":"6703","DOI":"10.7150\/jca.34469","article-title":"Combination of PD-L1 expression and NLR as prognostic marker in patients with surgically resected non-small cell lung cancer","volume":"10","author":"Wang","year":"2019","journal-title":"J. Cancer"}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326003396?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326003396?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:45:10Z","timestamp":1790739910000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523326003396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":30,"alternative-id":["S1936523326003396"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2026.103003","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EORTC-1607-GITCG\/ABC-09: Open-label first-line, single-arm phase II study of CisGem combined with pembrolizumab in patients with advanced or metastatic biliary tract cancer","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2026.103003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103003"}}